Alpha Teknova, Inc. Expands Proprietary Aav-Tek Solutions Product Line to Deliver End-To-End Solutions for Gene Therapy Process Development
July 11, 2023 at 01:00 pm
Share
Alpha Teknova, Inc. launched the next set of reagents in the Company's proprietary product line, AAV-Tekâ„¢? Solutions. Available for purchase starting July 11, 2023 is a version of Teknova's AAV-Tek AEX Buffer Screening Kit for the AAV8 serotype, along with a suite of reagents to support the entire gene therapy workflow.
The AAV-Tek A EX Buffer Screening Kit was created to help streamline the identification of the ideal buffer formulation for use during AAV downstream processing, specifically during the anion exchange (AEX) purification step. Developed by Teknova's Research and Development team, the kit addresses critical pain points in the workflow by providing a selection of serotype-specific equilibration and elution buffers to optimize the separation of empty and full capsids during polishing. Teknova conducted a robust design of experiments across multiple AAV serotypes by monitoring four different critical quality attributes (infectivity, recovery, purity, and peak separation), to identify the optimal number of buffers for use across a variety of upstream workflows, transgenes, and downstream purification platforms. Teknova is also introducing a suite of 24 high-quality, off-the-shelf reagents as part of the Company's AAV-Tek Solutions product line, including cell lysis solutions, filtration wash buffers, and capture chromatography reagents.
Designed to address end-to-end upstream and downstream bioprocessing needs, this array of new solutions - including the AAV-Tek AEx Buffer Screening Kit - positions Teknova as a single-source partner for gene therapy developers to help them streamline and scale their end-to-end biomanufacturing process development and enter the clinic faster. Along with the kit for AAV2 launched previously, the AAV-TekAEX Buffer Screening Kit for AAV8 is available for purchase via phone, email, or online, and is priced at $1,000. Teknova is continuing to work on additional serotypes - AAV6, AAV9, and AAV5 - for release later this year.
Alpha Teknova, Inc. is a producer of critical reagents for the research, discovery, development, and commercialization of therapies, vaccines, and molecular diagnostics. It offers two primary business lines, which include lab essentials and clinical solutions. It also offers three primary product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. The Company offers its liquid cell culture media and supplements and molecular biology reagents in both of its two product categories; pre-poured media plates are available in its Lab Essentials category only. Its customers include pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions developing vaccines and therapies and performing basic research.
ALPHA TEKNOVA, INC. 
